Results 31 to 40 of about 140,447 (354)

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy

Advances in Radiation Oncology, 2018
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
Neha P. Amin, MD, Maliha Zainib, BS, Sean M. Parker, BS, Manuj Agarwal, MD, Malcolm D. Mattes, MD   +4 more
doaj   +1 more source

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer

Cancer Control, 2021
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are ...
Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, Akihisa Fujita, Hideki Sato   +8 more
doaj   +1 more source

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Frontiers in Oncology, 2021
BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure.
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang   +8 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Journal for ImmunoTherapy of Cancer, 2019
Background Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown.
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini   +8 more
doaj   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core  

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small‐cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit.
M. Hellmann, T. Ciuleanu, A. Płużański, J. Lee, G. Otterson, C. Audigier-Valette, E. Minenza, H. Linardou, S. Burgers, P. Salman, H. Borghaei, S. Ramalingam, J. Brahmer, M. Reck, K. O'Byrne, W. Geese, G. Green, Han-Cheng Chang, J. Szustakowski, P. Bhagavatheeswaran, D. Healey, Yali Fu, F. Nathan, L. Paz-Ares   +23 more
semanticscholar   +1 more source

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

BMC Cancer, 2022
Background The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking.
T. Waddell, K. Fife, R. Griffiths, A. Sharma, P. Dhokia, L. Groves, M. Hurst, C. Tsang, D. Sugrue, S. McKenna, J. Houghton, R. Carroll   +11 more
doaj   +1 more source

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BMC Pulmonary Medicine, 2018
Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated
N. Koyama, O. Iwase, E. Nakashima, K. Kishida, T. Kondo, Y. Watanabe, H. Takahashi, Y. Umebayashi, Y. Ogawa, H. Miura   +9 more
doaj   +1 more source